Asymchem Laboratories (Tianjin) Co., Ltd. and AUM Biosciences Pte. Ltd. announced a collaboration agreement. Under the terms of the agreement, AUM and Asymchem agree to collaborate on the process development, and the clinical and commercial production, of AUM 601, which is a highly selective oral small molecule inhibitor of the tropomyosin receptor kinase (TRK) for treating rare cancers.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
82.65 CNY | -1.82% | +2.05% | -28.81% |
04-29 | Asymchem Laboratories' Profit Drops 55%, Operating Income Slumps 38% in Q1; Shares Up 3% | MT |
04-26 | Nomura Adjusts Asymchem Laboratories’ Price Target to HK$83.94 From HK$90.12 Keeps at Buy | MT |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-28.81% | 3.99B | |
+28.50% | 662B | |
+22.23% | 546B | |
-4.93% | 359B | |
+16.97% | 323B | |
+4.08% | 289B | |
+13.68% | 234B | |
+3.84% | 198B | |
-10.35% | 194B | |
+3.98% | 167B |
- Stock Market
- Equities
- 002821 Stock
- News Asymchem Laboratories (Tianjin) Co., Ltd.
- AUM Biosciences Identifies Asymchem as the CDMO Partner of Choice for their Novel TRK inhibitor